

## Rising Severe Sunburn Cases Drive Growth: Key Factor Shaping the Advanced Melanoma Market in 2025

The Business Research Company's Rising Severe Sunburn Cases Drive Growth: Key Factor Shaping the Advanced Melanoma Market in 2025

LONDON, GREATER LONDON, UNITED KINGDOM, March 24, 2025 /EINPresswire.com/ --Updated 2025 Market Reports Released: Trends, Forecasts to 2034 –

Early Purchase Your Competitive Edge Today!



Why Is The Advanced Melanoma Market Witnessing Robust Growth?



It will grow to \$5.90 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%."

The Business Research

Company

The advanced melanoma market has shown a solid growth upward trend in the recent years. It is expected to rise from a previous \$3.77 billion in 2024 to \$4.13 billion in 2025 at a compound annual growth rate CAGR of 9.4%. This growth in the historic period has primarily been propelled by factors such as the approval of dacarbazine, development of interferon therapy, introduction of ipilimumab, adoption of radiation therapy, the emergence

of combination therapies, approval of nivolumab, and the launch of pembrolizumab.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21088&type=smp

What is the Anticipated Growth Trajectory of the Advanced Melanoma Market?

The <u>advanced melanoma market size</u> is projected to continue its strong growth trajectory in the next few years, rising to an estimated \$5.90 billion in 2029 at a compound annual growth rate CAGR of 9.3%. This anticipated growth during the forecast period is primarily attributable to the

development of novel checkpoint inhibitors, a rise in personalized medicine, progress in adoptive cell therapy, an increasing use of combination therapies, the emergence of bispecific antibodies, the expansion of oncolytic virotherapy, and a growing focus on early detection tools. Some of the key trends shaping the forecast period include AI-powered diagnostic tools, mRNA-based cancer vaccines, CRISPR-based gene editing, oncolytic virus engineering, liquid biopsy technologies, wearable health monitoring devices, advanced imaging techniques, 3D bioprinting for research, tumor microenvironment modeling, and nanotechnology-driven drug delivery systems.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/advanced-melanoma-global-market-report

Why Are Severe Sunburns Influential To The Growth of the Advanced Melanoma Market?

The increasing prevalence of severe sunburn cases is expected to be a significant driving factor propelling the future growth of the advanced melanoma market. Such severe sunburns, which are intense skin burns caused by excessive exposure to ultraviolet UV radiation, lead to redness, pain, swelling, and sometimes blistering. The increasing incidence of severe sunburns is primarily due to a combination of factors such as prolonged exposure to ultraviolet radiation, lack of adequate sun protection measures, an increase in outdoor activities during peak UV hours, and a rise in global temperatures due to climate change.

Who Are The Key Industry Players In The Advanced Melanoma Market?

The formidable landscape of the advanced melanoma market includes major companies like Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., and Lytix Biopharma.

What Are The Emerging Innovations In The Advanced Melanoma Market?

Companies operating in the advanced melanoma market are focusing their attention on developing innovative products, such as personalized vaccines. These are a unique type of cancer treatment designed particularly for individual patients based on their own tumor's genetic mutations, thereby improving treatment efficacy, overcoming resistance mechanisms, and providing tailored treatment options that lead to better patient outcomes and extended survival.

How Is The Advanced Melanoma Market Segmented?

The advanced melanoma market report is divided into different segments. By therapeutics, it is categorized into Chemotherapy, Biological Therapy, Targeted Therapy, and Immune Therapy. By distribution channel, it is segmented into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. By end-user, it includes Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, and Other End Users. Further sub-segments include Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs under Chemotherapy, Monoclonal Antibodies, Interferons, Interleukins under Biological therapy, BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies under Targeted therapy, and Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, and Adoptive Cell Transfer under Immune Therapy.

Which Geographical Regions Dominate The Advanced Melanoma Market?

In terms of the geographical landscape, North America is the largest regional market for advanced melanoma as of 2024. The fastest-growing region projected in the forecast period, however, is Asia-Pacific. The report covers a range of geographical regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa in the advanced melanoma market report.

Discover more market report by <u>The Business Research Company</u>: Pheochromocytoma Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report">https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report</a>

Melanoma Drugs Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report">https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report</a>

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report">https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report</a>

About The Business Research Company

Learn More About The Business Research Company. With an impressive collection of over 15000+ reports from 27 industries covering over 60+ geographies, The Business Research Company has built a solid reputation for offering comprehensive, data-rich research and insights. Delivering information through 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, it's the ultimate tool you need to stay ahead of the game.

Contact us at:

The Business Research Company: <a href="https://www.thebusinessresearchcompany.com/">https://www.thebusinessresearchcompany.com/</a> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company">https://in.linkedin.com/company/the-business-research-company</a> YouTube: https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/796540385

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.